Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
AFFY's Cash to Debt is ranked higher than
87% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. AFFY: No Debt )
AFFY' s 10-Year Cash to Debt Range
Min: 6.71   Max: 13531.29
Current: No Debt

6.71
13531.29
Equity to Asset 0.96
AFFY's Equity to Asset is ranked higher than
98% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AFFY: 0.96 )
AFFY' s 10-Year Equity to Asset Range
Min: -3.14   Max: 0.96
Current: 0.96

-3.14
0.96
F-Score: 6
Z-Score: -131.14
M-Score: -12.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -13014.29
AFFY's Operating margin (%) is ranked lower than
51% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. AFFY: -13014.29 )
AFFY' s 10-Year Operating margin (%) Range
Min: -45958.11   Max: -12.84
Current: -13014.29

-45958.11
-12.84
Net-margin (%) 6414.29
AFFY's Net-margin (%) is ranked higher than
100% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. AFFY: 6414.29 )
AFFY' s 10-Year Net-margin (%) Range
Min: -44021.62   Max: -12.51
Current: 6414.29

-44021.62
-12.51
ROE (%) 1562.65
AFFY's ROE (%) is ranked higher than
100% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. AFFY: 1562.65 )
AFFY' s 10-Year ROE (%) Range
Min: -3010.47   Max: -20.19
Current: 1562.65

-3010.47
-20.19
ROA (%) 24.16
AFFY's ROA (%) is ranked higher than
98% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. AFFY: 24.16 )
AFFY' s 10-Year ROA (%) Range
Min: -154.34   Max: -8.21
Current: 24.16

-154.34
-8.21
ROC (Joel Greenblatt) (%) -3249.70
AFFY's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. AFFY: -3249.70 )
AFFY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4200.95   Max: -305.75
Current: -3249.7

-4200.95
-305.75
Revenue Growth (%) -79.40
AFFY's Revenue Growth (%) is ranked higher than
56% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. AFFY: -79.40 )
AFFY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 187
Current: -79.4

0
187
EBITDA Growth (%) -7.50
AFFY's EBITDA Growth (%) is ranked higher than
75% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. AFFY: -7.50 )
AFFY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 25
Current: -7.5

0
25
EPS Growth (%) -11.90
AFFY's EPS Growth (%) is ranked higher than
73% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. AFFY: -11.90 )
AFFY' s 10-Year EPS Growth (%) Range
Min: -65.5   Max: 17.4
Current: -11.9

-65.5
17.4
» AFFY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AFFY Guru Trades in

AFFY Guru Trades in

Q1 2013

AFFY Guru Trades in Q1 2013

Paul Tudor Jones 305,400 sh (New)
Jim Simons 1,027,867 sh (New)
Steven Cohen Sold Out
» More
Q2 2013

AFFY Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-03-31 Sold Out 0.06%$6.53 - $14.31 $ 0.11-99%0
George Soros 2011-12-31 Add 800.9%0.05%$4.24 - $7.8 $ 0.11-98%200000
George Soros 2011-09-30 Reduce -83.4%0.01%$4.04 - $7.78 $ 0.11-98%22200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 1.50
AFFY's P/E(ttm) is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AFFY: 1.50 )
AFFY' s 10-Year P/E(ttm) Range
Min: 0   Max: 6.4
Current: 1.5

0
6.4
P/B 0.64
AFFY's P/B is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. AFFY: 0.64 )
AFFY' s 10-Year P/B Range
Min: 0.89   Max: 172
Current: 0.64

0.89
172
EV-to-EBIT -0.02
AFFY's EV-to-EBIT is ranked higher than
70% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AFFY: -0.02 )
AFFY' s 10-Year EV-to-EBIT Range
Min: -21.7   Max: 2.2
Current: -0.02

-21.7
2.2
Current Ratio 20.81
AFFY's Current Ratio is ranked higher than
95% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. AFFY: 20.81 )
AFFY' s 10-Year Current Ratio Range
Min: 0.62   Max: 21.42
Current: 20.81

0.62
21.42
Quick Ratio 20.81
AFFY's Quick Ratio is ranked higher than
95% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. AFFY: 20.81 )
AFFY' s 10-Year Quick Ratio Range
Min: 0.62   Max: 21.42
Current: 20.81

0.62
21.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.13
AFFY's Price/Net Cash is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. AFFY: 1.13 )
AFFY' s 10-Year Price/Net Cash Range
Min: 1.17   Max: 60.08
Current: 1.13

1.17
60.08
Price/Net Current Asset Value 1.13
AFFY's Price/Net Current Asset Value is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. AFFY: 1.13 )
AFFY' s 10-Year Price/Net Current Asset Value Range
Min: 1.08   Max: 66.29
Current: 1.13

1.08
66.29
Price/Tangible Book 0.64
AFFY's Price/Tangible Book is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. AFFY: 0.64 )
AFFY' s 10-Year Price/Tangible Book Range
Min: 0.76   Max: 120
Current: 0.64

0.76
120
Price/Graham Number 0.19
AFFY's Price/Graham Number is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AFFY: 0.19 )
AFFY' s 10-Year Price/Graham Number Range
Min: 0.23   Max: 0.23
Current: 0.19

Earnings Yield (Greenblatt) -5000.00
AFFY's Earnings Yield (Greenblatt) is ranked lower than
54% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. AFFY: -5000.00 )
AFFY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 44.6   Max: 6367.2
Current: -5000

44.6
6367.2
Forward Rate of Return (Yacktman) -3040.74
AFFY's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. AFFY: -3040.74 )
AFFY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -409   Max: 7238.6
Current: -3040.74

-409
7238.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:A5Y.Germany
Affymax Inc was incorporated in Delaware in July 2001. The Company is a biopharmaceutical company in the process of restructuring operations. In March 2012, the U.S. Food and Drug Administration, or FDA, approved the Company's first and only product, OMONTYS or peginesatide Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S. In March 2013, Company implemented plans to restructure its operations in order to reduce operating costs and focus on the OMONTYS safety and other related FDA issues associated with the recall of the product. Until the product recall in February 2013, final OMONTYS drug product was manufactured as a buffered aqueous solution for intravenous or subcutaneous administration. Under its collaboration with Takeda, Company was responsible, through its contract manufacturing organizations, or CMOs, for the manufacture and supply of all quantities of OMONTYS active pharmaceutical ingredient, or API, to be used in development and commercialization around the world, and Takeda was responsible for final drug product manufacture and control. In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK